• Publications
  • Influence
Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement
The objective of this study was to investigate whether metabolic tumor volume (MTV) by positron emission tomography (PET) can be a potential prognostic tool when compared with Ann Arbor stage, inExpand
  • 91
  • 11
A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis.
BACKGROUND The clinical outcome of extranodal natural killer T-cell lymphoma (ENKTL) has improved substantially as a result of new treatment strategies with non-anthracycline-based chemotherapies andExpand
  • 127
  • 7
Leptomeningeal Carcinomatosis in Gastric Cancer
We analyzed 19 cases of cytologically confirmed leptomeningeal carcinomatosis (LMC) treated at our institution over the past 11 years. LMC was the initial manifestation of gastric cancer in 2Expand
  • 78
  • 6
Sarcopenia and inflammation are independent predictors of survival in male patients newly diagnosed with small cell lung cancer
PurposeSarcopenia is suggested to be associated with cancer-related inflammation. We assessed the clinical outcome of small cell lung cancer (SCLC) patients according to sarcopenia and theExpand
  • 48
  • 5
  • PDF
Human adipose tissue-derived mesenchymal stem cells protect kidneys from cisplatin nephrotoxicity in rats.
Cisplatin has multiple cellular targets and modes of action that lead to nephrotoxicity. This suggests novel therapies that act at multiple cisplatin target sites may be effective. We tested whetherExpand
  • 69
  • 4
  • PDF
Pulmonary marginal zone B-cell lymphoma of MALT type—What is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL)
AbstractsPulmonary marginal zone B-cell lymphoma of the MALT type (P-MZL) is a relatively rare form of lymphoma. We conducted a retrospective analysis of the clinical features and treatment outcomesExpand
  • 44
  • 4
Prognostic value of metabolic tumor volume on PET / CT in primary gastrointestinal diffuse large B cell lymphoma
Primary gastrointestinal (PGI) diffuse large B cell lymphoma (DLBCL) is a relatively common disease. Recent studies indicate that measurement of maximum standardized uptake value (SUVmax) onExpand
  • 51
  • 4
Phase II trial of S-1 in combination with gemcitabine for chemo-naïve patients with locally advanced or metastatic pancreatic cancer
BackgroundWe performed a phase II study of combination chemotherapy with S-1 plus gemcitabine for treating chemo-naïve patients with unresectable pancreatic cancer to evaluate the efficacy andExpand
  • 30
  • 3
High total metabolic tumor volume in PET/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab era.
Bone marrow involvement (BMI) in diffuse large B cell lymphoma (DLBCL) was naively regarded as an adverse clinical factor. However, it has been unknown which factor would separate clinical outcomesExpand
  • 27
  • 3
Combination Chemotherapy With Gemcitabine and Cisplatin as First-Line Treatment for Immunohistochemically Proven Cholangiocarcinoma
Objectives:The aim of this study was to determine the efficacy and safety profile of gemcitabine plus cisplatin in patients with immunohistochemically proven unresectable cholangiocarcinoma. PatientsExpand
  • 69
  • 2